Compare AMC & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMC | VOR |
|---|---|---|
| Founded | 1920 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 577.2M | 562.6M |
| IPO Year | 2007 | 2021 |
| Metric | AMC | VOR |
|---|---|---|
| Price | $0.95 | $14.42 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $2.03 | ★ $44.13 |
| AVG Volume (30 Days) | ★ 23.3M | 739.6K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2.86 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,848,900,000.00 | N/A |
| Revenue This Year | $10.60 | N/A |
| Revenue Next Year | $4.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.57 | N/A |
| 52 Week Low | $0.93 | $0.13 |
| 52 Week High | $4.08 | $49.95 |
| Indicator | AMC | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 26.81 | 53.82 |
| Support Level | N/A | $11.27 |
| Resistance Level | $1.25 | $14.73 |
| Average True Range (ATR) | 0.05 | 1.13 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 12.85 | 53.37 |
AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. The company owns, operates, or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, and premium presentation. The company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.